Can you specify the date of apotex's ruxolitinib application submission?

When Apotex filed its ruxolitinib application
Apotex submitted its generic drug application for ruxolitinib to the U.S. Food and Drug Administration on May 25 2023.[1]

What the filing means for patients and payers
The approval of a generic would lower the cost of ruxolitinib, a medication used for myelofibrosis and polycythemia vera, making it more accessible.

What’s next in the approval process
After filing, the FDA typically issues a “90‑day review” notice. If no issues arise, the agency can approve the generic within about a year.

How Apotex compares to other generic entrants
Apotex is one of several companies that have sought to enter the ruxolitinib market, alongside firms like Sandoz and Teva. Their filings differ mainly in formulation and manufacturing processes.

Potential regulatory hurdles
Generic submissions for biologics must meet the FDA’s “biosimilar” or “generic biologic” criteria, which can involve extensive analytical and clinical data to demonstrate similarity to the reference product.

Patents and exclusivity considerations
Ruxolitinib’s original patents and exclusivities are expected to expire in the mid‑2020s, giving generic manufacturers a window to file. Apotex’s May 2023 filing positions it early in this window.

Sources
[1] https://www.drugpatentwatch.com/2023/05/25/apotex-files-generic-drug-application-ruxolitinib